Clinical Trials Logo

Post-Herpetic Neuralgia clinical trials

View clinical trials related to Post-Herpetic Neuralgia.

Filter by:

NCT ID: NCT01848730 Completed - Clinical trials for Post-herpetic Neuralgia

Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia

Start date: April 2013
Phase: Phase 2
Study type: Interventional

To investigate the effect of repeat oral dosing of CNV2197944 75 mg tid on the pain experienced in post-herpetic neuralgia (PHN) as measured by changes in PI-NRS after three weeks of treatment compared to the baseline period.

NCT ID: NCT01752699 Completed - Clinical trials for Post-herpetic Neuralgia

Methadone in Post-Herpetic Neuralgia Pain

NPH
Start date: January 1998
Phase: Phase 3
Study type: Interventional

Neuropathic pain is a common condition and affecting 40 to 70% of the general population. Post-herpetic neuralgia is a condition almost complex and requires a multi modal treatment. Aim: This is a pilot proof-of-principle study designed to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line treatment for post-herpetic neuralgia (PHN) and had indication for the association of an opioid agent to their current drug regimen.

NCT ID: NCT01748877 Completed - Clinical trials for Post Herpetic Neuralgia

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

Start date: January 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate whether NXN-462, a selective nNOS inhibitor, is effective in reducing pain levels in patients with post-herpetic neuralgia.

NCT ID: NCT01426230 Completed - Clinical trials for Post Herpetic Neuralgia

Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia

Start date: September 2011
Phase: N/A
Study type: Observational

Study objective is to assess the safety and effectiveness of once- daily GRALISE in clinical practice

NCT ID: NCT01270828 Completed - Clinical trials for Post Herpetic Neuralgia

Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia

Start date: March 2011
Phase: Phase 3
Study type: Interventional

The purpose of the study is to explore the safety and efficacy of a new once a day pregabalin formulation versus placebo for patients with post herpetic neuralgia (Shingles)

NCT ID: NCT01250561 Completed - Herpes Zoster Clinical Trials

Reduction of Postherpetic Neuralgia in Herpes Zoster

Start date: February 2002
Phase: N/A
Study type: Interventional

The addition of gabapentin therapy to standard antiviral treatment with valacyclovir in acute herpes zoster patients will decrease the incidence of post-herpetic neuralgia.

NCT ID: NCT01124097 Terminated - Clinical trials for Post Herpetic Neuralgia

Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia

Start date: September 2010
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to assess the efficacy of Eslicarbazepine acetate (ESL) as therapy in subjects with Post-herpetic Neuralgia (PHN) over a 15 week treatment phase.

NCT ID: NCT01037088 Completed - Multiple Sclerosis Clinical Trials

Effects of Vaporized Marijuana on Neuropathic Pain

Start date: December 2009
Phase: Phase 1/Phase 2
Study type: Interventional

This study theorized that a low dose of vaporized cannabis could alleviate nerve injury pain.

NCT ID: NCT00475904 Completed - Neuropathy Clinical Trials

A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)

Start date: July 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare EpiCept™ NP-1 Topical Cream (2% ketamine / 4% amitriptyline) vs. Oral Gabapentin in the treatment of Postherpetic Neuralgia (PHN)

NCT ID: NCT00305357 Completed - Clinical trials for Post-Herpetic Neuralgia

Evolution of Pain From Herpes Zoster

Start date: November 2001
Phase:
Study type: Observational

Evolution of pain and neural injury will be evaluated at 2 years or longer after the onset of AHZ by multiple measures. Assessments at 2 years or longer will be compared to those collected during the first 6 months after HZ in order to test whether or not sensory function and cutaneous innervation continues to normalize beyond 6 months in subjects who recover from HZ without severe PHN.